Bicara Therapeutics Inc. Common Stock (BCAX) Financials
BCAX Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 512.2 million | 43.5 million |
| March 31, 2026 | 553.6 million | 39.6 million |
| Dec. 31, 2025 | 431.0 million | 29.5 million |
| Sept. 30, 2025 | 424.7 million | 21.9 million |
BCAX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -44.3 million | 8.2 million |
| March 31, 2026 | -37.6 million | 5.9 million |
| Dec. 31, 2025 | -24.1 million | 4.4 million |
| Sept. 30, 2025 | -29.3 million | 3.6 million |
BCAX Net Income
No data available :(
BCAX Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 497.3 million | - | - |
| March 31, 2026 | 539.8 million | 301000 | 1.1 million |
| Dec. 31, 2025 | 414.8 million | 593000 | 1.7 million |
| Sept. 30, 2025 | 290.2 million | 880000 | 1.1 million |
BCAX Shares Outstanding
BCAX Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 60000 | 45.8 million | 14.2 million | - |
| March 31, 2026 | 60000 | 47.5 million | 12.7 million | - |
| Dec. 31, 2025 | 238000 | 33.0 million | 8.1 million | - |
| Sept. 30, 2025 | 42000 | 5.8 million | 7.7 million | - |
BCAX Cost of Revenue
No data available :(
BCAX
Price: $24.49
52 week price:
Earnings Per Share: 5.38 USD
P/E Ratio: 3.33
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Market Capitalization: 1.5 billion